Fig. 2. β-arrestin-2 is upregulated under treatment of APC and OGD.

a Left panel showed western blot analysis using cell lysates from Matrigel. Right upper panel showed quantitative results of β-arrestin-1/β-actin ratio of western blot analysis (n = 4). Right lower panel showed quantitative results of β-arrestin-2/β-actin ratio of western blot analysis (n = 3–4). Data were analyzed compared with multiple groups by Kruskal–Wallis tests. *p < 0.05 compared with BBMCs on matrigel. b Left upper panel showed representative image of HUVECs using a miRNA control (miR Cont), knockdown of β-arrestin-2 by using miRNA (miR β arrestin-2) and overexpression of β-arrestin-2, left lower panel showed each sample tube-like capillary formation under treatment with APC (0.3 ng/mL). Scale bar was 100 µm. Right panel showed quantitative results. Results are means ± SEM (n = 6). Data were analyzed compared with multiple groups by Kruskal–Wallis tests. *p < 0.05. c Time course of TEER using knockdown of β-arrestin-2 HUVECs (miR βarrestin-2) compared with control HUVECs (miR Cont) showed (n = 4). d Permeability assay showed compared with control HUVECs (miR Cont) under no treatment (n = 6–9). Results are means ± SEM (n = 6–9). Data were analyzed compared with multiple groups by Kruskal–Wallis tests. *p < 0.05 compared with the HUVECs under no treatment. NS was meant not significantly changed